The interest in developing novel antipsychotics is especially keen at this time and this book presents the latest information in that development. Numerous compounds are in the preclinical and clinical pipeline. The pharmaceutical industry, as well as psychiatrists, clinicians, mental health professionals and anyone else interested in the design and conduct of clinical trials of schizophrenia, are waiting for these research results. Revealing recommendations for developing antipsychotic compounds based on the extensive experience of the authors, this work will provide long-awaited information on a previously unexplored area.
|Product dimensions:||6.20(w) x 9.49(h) x 0.70(d)|
Table of Contents
Introduction: The Worldwide Market for Antipsychotic Drugs.
Atypical Antipsychotics: Mechanisms, and Preclinical and Clinical Proflies.
Review of the Clinical Development of Atypical Antipsychotic Compounds.
Phase I Clinical Development and Finding the Dose: The Role of the Bridging Study.
General Methodological Issues in Antipsychotic Drug Development.
Special Methodological Issues in Antipsychotic Drug Development.
Concluding Remarks on Drug Development.